ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today presented 48-week data from the SALSA ...
In largest head-to-head randomized clinical trial evaluating the two medicines, Dovato (DTG/3TC) met the primary endpoint, demonstrating sustained non-inferior efficacy versus Biktarvy (BIC/FTC/TAF) ...
LONDON--(BUSINESS WIRE)-- ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, announces 48-week findings from PASO DOBLE (GeSIDA 11720 ...
In HIV treatment, Gilead Sciences’ popular Biktarvy serves as a benchmark for newer drugs to overcome. In a new head-to-head study, GSK’s two-drug regimen Dovato showed comparable antiviral efficacy ...
Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain experienced by participants taking Dovato ...
The MarketWatch News Department was not involved in the creation of this content. -- Dovato is now the first and only oral, two-drug, single-tablet regimen available for people aged 12 and older ...
ViiV Healthcare tapped real patients to help drill down into Dovato’s unique selling point to help promote the HIV drug—and it took that message far and wide with a boost in TV ad spending during ...
PASO DOBLE sub‑analysis indicates metabolic differences between 2‑drug and 3‑drug HIV regimens ViiV Healthcare has announced new 96‑week findings from a sub‑group analysis of the PASO DOBLE study, ...
The MarketWatch News Department was not involved in the creation of this content. -- Largest head-to-head randomised clinical trial between DTG/3TC and BIC/FTC/TAF, conducted by SEIMC-GeSIDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results